PeptideCompareCagrilintide — EU research guide.
Cagrilintide is a long-acting amylin analogue developed by Novo Nordisk, designed for once-weekly dosing. In combination with semaglutide (CagriSema), it has shown up to 22% weight loss in Phase 3 trials.
What is Cagrilintide?
Cagrilintide activates amylin receptors (CALCR + RAMPs) to reduce appetite, slow gastric emptying and suppress glucagon — mechanisms complementary to GLP-1 receptor agonism. It is not a GLP-1 analogue. Its half-life of ~7 days supports once-weekly administration.
What does the research show?
In the REDEFINE 1 Phase 3 trial (CagriSema 2.4mg semaglutide + 2.4mg cagrilintide), mean weight reduction reached ~22.7% at 68 weeks in people with obesity. Standalone cagrilintide produces modest weight loss (~8–10%); the combination is the primary clinical interest. Not yet EMA-approved as of mid-2026.
EU legal status
Not approved in the EU. Available from research suppliers as a laboratory peptide for mechanistic amylin-receptor research.
Molecular information
Pharmacokinetics
Potency retained over time
Each line is one storage condition: it starts at 100% and declines as potency is lost. Above the dotted 80% line the material is considered reliable — hover the chart for exact values.
⚠ Estimates modelled per component from molecular properties (chain length, cyclisation, oxidation- and deamidation-sensitive residues, light sensitivity). Indicative only — not lab-measured per batch.
Cagrilintide across EU suppliers
COA-verified EU vendors · Updated monthly
Frequently asked questions
What is Cagrilintide? ▾
Cagrilintide is an amylin analog that activates amylin receptors (CALCR with RAMPs) to reduce appetite, slow gastric emptying and suppress glucagon. It is not a GLP-1 analog, and its roughly 7-day half-life supports once-weekly dosing.
What does the research show? ▾
In the REDEFINE 1 Phase 3 trial the CagriSema combination (2.4 mg semaglutide plus 2.4 mg cagrilintide) reached about 22.7% mean weight reduction at 68 weeks in people with obesity, while standalone cagrilintide produces more modest weight loss of roughly 8 to 10%.
How is cagrilintide different from GLP-1 drugs? ▾
It works through amylin receptors rather than the GLP-1 receptor, a complementary mechanism, which is why it is primarily studied in combination with a GLP-1 agonist.
What is CagriSema? ▾
CagriSema is the combination of cagrilintide with semaglutide, which is the primary clinical interest and reached about 22.7% weight reduction in the REDEFINE 1 trial.
Is cagrilintide approved in the EU? ▾
No. It is an investigational compound not yet EMA-approved as of mid-2026, available from research suppliers for laboratory amylin-receptor research.
Is cagrilintide banned in sport? ▾
It is not currently on the WADA prohibited list.
References
- Phase 2, 26-week, placebo- and active-controlled dose-finding trial of cagrilintide monotherapy for obesity, including a head-to-head liraglutide comparator arm. Lau DCW, et al. Lancet. 2021;398(10307):2160–2172. DOI